10-YEAR DYNAMICS OF HELICOBACTER PYLORI INFECTION PREVALENCE IN PERSONS OF CONSCRIPTION AGE AND DATA ON PRIMARY RESISTANCE TO CLARITHOMYCIN
Abstract
Вackground. Data on Helicobacter pylori (H. pylori) infection prevalence are of significant scientific and practical importance. Objective. To assess the dynamics of H. pylori infection prevalence from 2010-2013 to 2020-2023 among men aged 18-26 with dyspepsia and to determine the primary resistance of H. pylori to clarithromycin. Material and methods. The frequency of H. pylori contamination of the gastric mucosa (GM) in men aged 18-26 with dyspepsia was studied using morphological methods over the periods of 2010-2013 (n=239) and 2020-2023 (n=607). Real-time polymerase chain reaction (PCR) was used to detect mutations in the 23S rRNA gene responsible for clarithromycin resistance (samples: GM biopsies) in 59 men aged 18-26 who had not undergone eradication therapy or had no known history of clarithromycin use. Results. During the period of 2010-2013, the frequency of H. pylori infection among conscripted military personnel was 65.3% (95% CI 59.1-71.1) and decreased to 49.3% (95% CI 45.3-53.2; χ²=17.69, p<0.001) by 2020-2023. Among conscripts from urban settlements, the frequency of H. pylori infection decreased from 68.4% (95% CI 60.7-75.1) to 46.7% (95% CI 42.2-51.2; χ²=22.24, p<0.001); among those from rural settlements, the decrease was not statistically significant (χ²=0.056, p=0.814). A statistically significant decrease in the frequency of H. pylori was noted in the group with cicatricial and ulcerative deformity of the gastroduodenal region without ulcerative defect, as well as with chronic gastritis. Among 59 patients with/without dyspepsia, point mutations A2143G/A2142G in the 23S ribosomal RNA gene of H. pylori were detected in 11 individuals (18.6%; 95% CI 10,7-30,4). Conclusion. In 2020-2023 compared to 2010-2013, there was a reduction in the frequency of H. pylori infection among conscription-age individuals (18-26 years) with dyspepsia, from 65.3% (95% CI 59.1-71.1) to 49.3% (95% CI 45.3-53.2; χ²=17.69, p<0.001), mainly due to a decrease among conscripts from urban settlements, in groups with cicatricial and ulcerative deformity of the gastroduodenal region without ulcerative defect, with chronic gastritis. Primary resistance of H. pylori to clarithromycin was found in 11 of 59 men (18.6%; 95% CI 10,7-30,4) tested.
References
Marahovskij KJu. Soprjazhennost izmenenij slizistoj zheludka, associirovannoj c Нelicobacter pylori, u detej i vzroslyh v urbanizirovannoj populjacii. Medicinskije novosti. 2004;(9):17-23. [Internet]. Available from: https://www.mednovosti.by/journal.aspx?article=2034 (Russian).
Pimanau S, Makarenka A, Voropaeva AV. Prevalence of Helicobacter pylori infection among asymptomatic young adult population and patients with duodenal ulcer: study in Belarus. Helicobacter. 2004;9(5):516-517. https://doi.org/10.1111/j.1083-4389.2004.00255-6.x. https://www.elibrary.ru/perxfv.
Li Y, Choi H, Leung K, Jiang F, Graham DY, Leung WK. Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(6):553-564. https://doi.org/10.1016/S2468-1253(23)00070-5.
World Health Organization. WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Available from: https://www.who.int/en/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.
Bujanda L, Nyssen OP, Vaira D, Saracino IM, Fiorini G, Lerang F, Georgopoulos S, Tepes B, Heluwaert F, Gasbarrini A, Rokkas T, Bordin D, Smith S, Lamy V, Caldas M, Resina E, Muñoz R, Cosme Á, Puig I, Megraud F, O'Morain C, Gisbert JP. Antibiotic Resistance Prevalence and Trends in Patients Infected with Helicobacter pylori in the Period 2013-2020: Results of the European Registry on H. pylori Management (Hp-EuReg). Antibiotics (Basel). 2021;10(9):1058. https://doi.org/10.3390/antibiotics10091058.
Bodunova N, Tsapkova L, Polyakova V, Baratova I, Rumyantsev K, Dekhnich N, Nikolskaya K, Chebotareva M, Voynovan I, Parfenchikova E, Pronina G, Chernikova E, Bordin D. Genetic Markers of Helicobacter pylori Resistance to Clarithromycin and Levofloxacin in Moscow, Russia. Curr Issues Mol Biol. 2024;46(7):6665-6674. https://doi.org/10.3390/cimb46070397.
Mégraud F, Graham DY, Howden CW, Trevino E, Weissfeld A, Hunt B, Smith N, Leifke E, Chey WD. Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe. Am J Gastroenterol. 2023;118(2):269-275. https://doi.org/10.14309/ajg.0000000000002045.
Voropaeva A, Voropaev E, Baranov O, Platoshkin E, Shafransky A, Pimanov S, Makarenko E. Molekuljarno-geneticheskoje testirovanije mutacij gena 23S rRNK Helicobacter pylori, opredeljajushchih rezistentnost k klaritromicinu v Belarusi [Molecular-genetic testing of 23S rRNA Helicobacter pylori Gene Mutations Defining Resistance to Clarithromycin in Belarus]. Mediko-biologicheskije problemy zhiznedejatelnosti. 2010;1(3):30-35. edn: NXZFXZ. (Russian).
Yanovich OO, Nosova ES, Titov LP, Doroshko MV. Ocenka rezistentnosti Helicobacter pylori k klaritromicinu metodom PCR u bolnyh helikobakteriozom [Assessment of Helicobacter pylori Resistance to Clarithromycin in Patients with Helicobacteriosis by PCR method]. Zdravoohranenije (Minsk). 2011;(12):9-12. edn: ROCUGP. (Russian).
Janovich OO, Titov LP, Doroshko MV. Associacija mutacij v gene 23S rRNK Helicobacter pylori, svjazannyh s rezistentnostju k Klaritromicinu, s aktivnostju vospalenija i morfologicheskimi izmenenijami slizistoj obolochki zheludka. In: Gorbunov VA, Amvrosjeva TV, Boreko EI, Titov LP, Poleshhuk NN, Samojlova TI, Samojlovich EO, Chistenko GN, editors. Sovremennye problemy infekcionnoj patologii cheloveka. Sbornik nauchnyh trudov. Minsk: Izdatelskij centr BGU; 2022. Iss. 14. p. 109-113. (Russian).
Bakulina NV, Tikhonov SV, Savilova IV, Zharkov AV, Ponomarenko VA. Dinamika rasprostranennosti infekcii Helicobacter pylori s 2015 po 2023 gody [Dynamics of the prevalence of helicobacter pylori infection from 2015 to 2023]. Vestnik Severo-Zapadnogo gosudarstvennogo medicinskogo universiteta im. I.I. Mechnikova [Herald of North-Western State Medical University named after I. I. Mechnikov]. 2023;15(3):41-51. https://doi.org/10.17816/mechnikov623259. https://www.elibrary.ru/zcdouq. (Russian).
Jonaityte IR, Ciupkeviciene E, Jonaitis P, Kupcinskas J, Petkeviciene J, Jonaitis L. Changes in the Seroprevalence of Helicobacter pylori among the Lithuanian Medical Students over the Last 25 Years and Its Relation to Dyspeptic Symptoms. Medicina (Kaunas). 2021;57(3):254. https://doi.org/10.3390/medicina57030254.
Antunes R, Oleastro M, Nogueira JP, Lopes AI. Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019. Helicobacter. 2023;28(4):e12963. https://doi.org/10.1111/hel.12963.
Zou JC, Wen MY, Huang Y, Chen XZ, Hu JK. Helicobacter pylori infection prevalence declined among an urban health check-up population in Chengdu, China: a longitudinal analysis of multiple cross-sectional studies. Front Public Health. 2023;11:1128765. https://doi.org/10.3389/fpubh.2023.1128765.
Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, Bazzoli F, Gasbarrini A, Atherton J, Graham DY, Hunt R, Moayyedi P, Rokkas T, Rugge M, Selgrad M, Suerbaum S, Sugano K, El-Omar EM; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. https://doi.org/10.1136/gutjnl-2016-312288.
Silivonchik NN, Pimanov SI. Lekarstvennyje preparaty vismuta v klinicheskoj praktike. Minsk: Ekoperspektiva; 2024. 43 p. (Russian).
1.png)
